MOLECULES OF THE MILLENNIUM
Year : 2014 | Volume
: 5 | Issue : 3 | Page : 222--224
Delamanid: A new armor in combating drug-resistant tuberculosis
Alphienes Stanley Xavier, Mageshwaran Lakshmanan
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India
Correspondence Address:
Alphienes Stanley Xavier
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry - 605 006
India
Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.
How to cite this article:
Xavier AS, Lakshmanan M. Delamanid: A new armor in combating drug-resistant tuberculosis.J Pharmacol Pharmacother 2014;5:222-224
|
How to cite this URL:
Xavier AS, Lakshmanan M. Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother [serial online] 2014 [cited 2021 Jan 22 ];5:222-224
Available from: http://www.jpharmacol.com/article.asp?issn=0976-500X;year=2014;volume=5;issue=3;spage=222;epage=224;aulast=Xavier;type=0 |
|
